caNanoLab: data sharing to expedite the use of nanotechnology in biomedicine

The use of nanotechnology in biomedicine involves the engineering of nanomaterials to act as therapeutic carriers, targeting agents and diagnostic imaging devices. The application of nanotechnology in cancer aims to transform early detection, targeted therapeutics and cancer prevention and control. To assist in expediting and validating the use of nanomaterials in biomedicine, the National Cancer Institute (NCI) Center for Biomedical Informatics and Information Technology, in collaboration with the NCI Alliance for Nanotechnology in Cancer (Alliance), has developed a data sharing portal called caNanoLab. caNanoLab provides access to experimental and literature curated data from the NCI Nanotechnology Characterization Laboratory, the Alliance and the greater cancer nanotechnology community.

Gold nanoparticles reduced in situ and dispersed in polymer thin films: optical and thermal properties

Optical and thermal activity of plasmon-active nanoparticles in transparent dielectric media is of growing interest in thermal therapies, photovoltaics and optoelectronic components in which localized surface plasmon resonance (LSPR) could play a significant role. This work compares a new method to embed gold nanoparticles (AuNPs) in dense, composite films with an extension of a previously introduced method. Microscopic and spectroscopic properties of the two films are related to thermal behavior induced via laser excitation of LSPR at 532 nm in the optically transparent dielectric. Gold nanoparticles were incorporated into effectively nonporous 680 μm thick polydimethylsiloxane (PDMS) films by (1) direct addition of organic-coated 16 nm nanoparticles; and (2) reduction of hydrogen tetrachloroaurate (TCA) into AuNPs. Power loss at LSPR excitation frequency and steady-state temperature maxima at 100 mW continuous laser irradiation showed corresponding increases with respect to the mass of gold introduced into the PDMS films by either method. Measured rates of temperature increase were higher for organic-coated NP, but higher gold content was achieved by reducing TCA, which resulted in larger overall temperature changes in reduced AuNP films.

Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance

Historically, treatment of patients with cancer using chemotherapeutic agents has been associated with debilitating and systemic toxicities, poor bioavailability, and unfavorable pharmacokinetics. Nanotechnology-based drug delivery systems, on the other hand, can specifically target cancer cells while avoiding their healthy neighbors, avoid rapid clearance from the body, and be administered without toxic solvents. They hold immense potential in addressing all of these issues, which has hampered further development of chemotherapeutics. Furthermore, such drug delivery systems will lead to cancer therapeutic modalities that are not only less toxic to the patient but also significantly more efficacious. In addition to established therapeutic modes of action, nanomaterials are opening up entirely new modalities of cancer therapy, such as photodynamic and hyperthermia treatments. Furthermore, nanoparticle carriers are also capable of addressing several drug delivery problems that could not be effectively solved in the past and include overcoming formulation issues, multidrug-resistance phenomenon, and penetrating cellular barriers that may limit device accessibility to intended targets, such as the blood-brain barrier. The challenges in optimizing design of nanoparticles tailored to specific tumor indications still remain; however, it is clear that nanoscale devices carry a significant promise toward new ways of diagnosing and treating cancer. This review focuses on future prospects of using nanotechnology in cancer applications and discusses practices and methodologies used in the development and translation of nanotechnology-based therapeutics.